Resource Logo
Agence France-Presse

Thalidomide, the birth defect drug


PARIS, Sept 1, 2012 (AFP) - Originally given to pregnant women half a century ago to limit morning sickness, thalidomide caused birth defects in thousands of babies, a tragedy for which the German firm that manufactured the drug officially apologised for the first time on Friday.

The sedative drug, made by Chemie Grunenthal and sold between 1957 and 1962, affected at least 10,000 babies in some 40 countries, especially in ermany, Britain, Australia and Canada. Some estimates put the number at nearer 20,000.

Children were born with stunted, twisted or missing limbs because thalidomide binds to, and deactives, a protein known as cereblon which helps forms limbs, research in the journal Science showed in 2010.

When the realisation dawned that thalidomide was teratogenic, the drug was withdrawn from the British and German markets, in late 1961. But it continued to be sold in Canada until August 1962, in Japan until September and in Belgium until December of that year.

The scandal led to a tightening of vetting procedures for drug prototypes and scrutiny of claims by pharmaceutical giants.

In recent years, though, interest in it has revived as a research tool but also as a treatment for diseases that attack the body's immune system including a form of cancer called multiple myeloma, and for inflammatory diseases such as lupus erythematosus and Crohn's diease.

It can also help relieve the side-effects from leprosy and severe mouth ulcers resulting from HIV infection.

Thalidomide is prescribed to patients only in very tightly controlled conditions and remains outlawed for general distribution.


Copyright © 2012 -Agence France-Presse, Publisher. All rights reserved to AFP articles contained on the AEGiS web site may not be reproduced, distributed,transmitted, displayed, published or broadcast without AFP's prior written permission. You may make one copy of each article for your personal, non-commercial use only; more copies would require AFP's prior written permission obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP photos or materials. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP stories, photos or graphics Agence France-Presse

Information in this article was accurate in September 1, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.